This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

April 30, 2003 — A meta-analysis of 21 studies supports the efficacy of amiodarone for converting atrial fibrillation (AF) to sinus rhythm and suggests that the drug has a differing magnitude of ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

It is now apparent that the problem associated with antiarrhythmic drugs is that any beneficial effects these agents may bring about by restoring and maintaining sinus rhythm is negated by their side ...

Conversion to sinus rhythm (SR) in patients with recent-onset atrial fibrillation (AF) ( Conversion to sinus rhythm (SR) in patients with recent-onset atrial fibrillation (AF) (<48 hours duration) was ...

Photo Credit: AHA/Scott Morgan 2022. Used with permission. CHICAGO, IL—Full results of the RAPID trial testing etripamil nasal spray for patients with paroxysmal supraventricular tachycardia (PSVT) ...

After AF treatment in hospital (either 450 mg propafenone or 200 mg flecainide if the patient weighed <70 kg, or 600 mg propafenone or 300 mg flecainide if the patient weighed ≥70 kg; drug selection ...

Please provide your email address to receive an email when new articles are posted on . Beta-blockers reduced mortality in individuals with HF with reduced ejection fraction in sinus rhythm regardless ...

CHICAGO -- Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with a population largely in ...